Studies report B12 levels drop by 1020% in some patients within 612 months of GLP-1 use, increasing risk of deficiency-related neuropathy and cognitive effects
Mitochondrial dysfunction and biogenesis in neurodegenerative diseases: Pathogenesis and treatment
Key Takeaways Triple agonist mechanism: Retatrutide is the first medication to activate GIP, GLP-1, and glucagon receptors simultaneously GLP-1 component reduces appetite and slows gastric emptying, the core appetite suppression pathway GIP component improves insulin sensitivity and promotes favorable fat distribution Glucagon component increases energy expenditure through thermogenesis and promotes fat breakdown Weight loss: Phase 2 trials showed up to 24.2% weight loss at 48 weeks, compared to tirzepatide (~22%) and semaglutide (~15%) Investigational status: Not FDA-approved
Partner with me on the KevinMD platform
They have shown only modest success, have poor compliance and are under prescribed
Scenesse (afamelanotide acetate, Clinuvel Pharmaceuticals) is an FDA-approved subcutaneous implant for the reduction of phototoxicity in adult patients with erythropoietic protoporphyria
